MedDataX Logo

A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients

NCT ID: NCT01330316

Last Updated: 2016-06-30

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

119 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-07-31

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this trial is to collect evidence for the safety and efficacy of 24 weeks of treatment with BI 201335 240 mg in combination with 24 or 48 weeks of Pegylated Interferon (PegIFN) and ribavirin (RBV) in treatment experienced patients who have been withdrawn from PegIFN and RBV treatment due to lack of efficacy in the 1220.7, 1220.30 and 1220.47 trials.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection

NCT01608737

Hepatitis C, Chronic
WITHDRAWN PHASE3

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

NCT01358864

Hepatitis C, Chronic
COMPLETED PHASE3

Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced

NCT00793793

Hepatitis C, Chronic
COMPLETED PHASE1

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)

NCT01297270

Hepatitis C
COMPLETED PHASE3

Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

NCT01132313

Hepatitis C, Chronic
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BI 201335 for 24 weeks

BI 201335 once daily dose for 24 weeks in combination with PegIFN/RBV for 24 or 48 weeks

Group Type EXPERIMENTAL

BI 201335

Intervention Type DRUG

BI 201335 for 24 weeks

PegIFN/RBV

Intervention Type DRUG

PegIFN/RBV for 48 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BI 201335

BI 201335 for 24 weeks

Intervention Type DRUG

PegIFN/RBV

PegIFN/RBV for 48 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Chronic hepatitis C infection of GT-1 in patients who failed prior treatment with PegIFN and RBV in the 1220.7, 1220.30 and 1220.47 trials of the BI 201335 Phase III program.

1. Patients from trials 1220.7, 1220.30 and 1220.47 of BI 201335 who have failed treatment with PegIFN/RBV in the placebo groups due to protocol-defined criteria of treatment failure (i.e. either non-response on treatment or relapse after end of treatment \[EOT\]).
2. Patients must have received at least 4 weeks of assigned trial medication and been compliant with all study procedures.
3. Female patients:

* with documented hysterectomy,
* who have had both ovaries removed,
* with documented tubal ligation,
* who are post-menopausal with last menstrual period at least 12 months prior to screening, or
* of childbearing potential with a negative serum pregnancy test at screening and Day 1, that, if sexually active, agree to use one of the appropriate medically accepted methods of birth control from the date of screening until 7 months after the last dose of RBV in addition to the consistent and correct use of a condom. Patients must agree not to breast-feed at any time from the date of screening until 7 months after the last dose of RBV.

Medically accepted methods of contraception for females in this trial are ethinyl estradiol-containing contraceptives, diaphragm with spermicide substance, intra-uterine device and cervical cap.

or

Male patients:
* who are documented to be sterile, or
* who are without pregnant female partner(s) and consistently and correctly use a condom while their female partner(s) (if of child-bearing potential) agree to use one of the appropriate medically accepted methods of birth control from the date of screening until 7 months after the last dose of ribavirin. It is in the responsibility of the male patient to ensure that his partner(s) is not pregnant prior to screening into the study or becomes pregnant during the treatment and the observation phase. Female partners of childbearing potential must perform monthly pregnancy tests from the date of screening until 7 months after the last dose of ribavirin (tests will be provided by the sponsor).
4. Signed informed consent form prior to trial participation.

Exclusion Criteria

2. HIV co-infection
3. Hepatitis B virus (HBV) infection based on presence of HBs-Ag
4. Active malignancy, or history of malignancy within the last 5 years prior to screening (with an exception of appropriately treated basal cell carcinoma of the skin or in situ carcinoma of the uterine cervix)
5. Active or, history of alcohol or illicit drug abuse other than cannabis within the past 12 months
6. A condition that is defined as one which in the opinion of investigator may put the patient at risk because of participation in this study, may influence the results of this study, or limit the patients ability to participate in this study
7. Usage of any investigational drugs within 30 days prior to screening, or planned usage of an investigational drug during the course of this study.
8. Received concomitant systemic antiviral, hematopoietic growth factor, or immunomodulatory treatment within 30 days prior to screening. Patients being treated with oral antivirals such as acyclovir, famciclovir or valacyclovir for recurrent herpes simplex infection; or with oseltamivir or zanamivir for influenza A infection, may be screened.
9. Received silymarin (milk thistle), glycyrrhizin, or Sho-saiko-to (SST) within 28 days prior to enrolment and throughout the treatment phase of this trial.
10. Known hypersensitivity to any ingredient of the study drugs.
11. Alpha fetoprotein value \> 100 ng/mL at screening; if \> 20 ng/mL and = 100 ng/mL, patients may be included if there is no evidence of liver cancer in an appropriate imaging study (e.g., ultrasound, CT scan, or MRI) within last 6 months prior to randomization (Visit 2).
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

1220.48.0004 Boehringer Ingelheim Investigational Site

Birmingham, Alabama, United States

Site Status

1220.48.0091 Boehringer Ingelheim Investigational Site

North Little Rock, Arkansas, United States

Site Status

1220.48.0011 Boehringer Ingelheim Investigational Site

Los Angeles, California, United States

Site Status

1220.48.0018 Boehringer Ingelheim Investigational Site

Oceanside, California, United States

Site Status

1220.48.0078 Boehringer Ingelheim Investigational Site

Fort Lauderdale, Florida, United States

Site Status

1220.48.0095 Boehringer Ingelheim Investigational Site

Palm Harbor, Florida, United States

Site Status

1220.48.0039 Boehringer Ingelheim Investigational Site

Columbus, Georgia, United States

Site Status

1220.48.0013 Boehringer Ingelheim Investigational Site

Chicago, Illinois, United States

Site Status

1220.48.0087 Boehringer Ingelheim Investigational Site

Baton Rouge, Louisiana, United States

Site Status

1220.48.0027 Boehringer Ingelheim Investigational Site

Framingham, Massachusetts, United States

Site Status

1220.48.0065 Boehringer Ingelheim Investigational Site

Springfield, Massachusetts, United States

Site Status

1220.48.0023 Boehringer Ingelheim Investigational Site

Tupelo, Mississippi, United States

Site Status

1220.48.0066 Boehringer Ingelheim Investigational Site

Neptune City, New Jersey, United States

Site Status

1220.48.0012 Boehringer Ingelheim Investigational Site

New York, New York, United States

Site Status

1220.48.0058 Boehringer Ingelheim Investigational Site

Portland, Oregon, United States

Site Status

1220.48.0063 Boehringer Ingelheim Investigational Site

Arlington, Texas, United States

Site Status

1220.48.0029 Boehringer Ingelheim Investigational Site

Austin, Texas, United States

Site Status

1220.48.0017 Boehringer Ingelheim Investigational Site

Dallas, Texas, United States

Site Status

1220.48.0071 Boehringer Ingelheim Investigational Site

Dallas, Texas, United States

Site Status

1220.48.0081 Boehringer Ingelheim Investigational Site

Forth Worth, Texas, United States

Site Status

1220.48.4301 Boehringer Ingelheim Investigational Site

Vienna, , Austria

Site Status

1220.48.4302 Boehringer Ingelheim Investigational Site

Vienna, , Austria

Site Status

1220.48.3201 Boehringer Ingelheim Investigational Site

Brussels, , Belgium

Site Status

1220.48.3204 Boehringer Ingelheim Investigational Site

Edegem, , Belgium

Site Status

1220.48.3203 Boehringer Ingelheim Investigational Site

Liège, , Belgium

Site Status

1220.48.1012 Boehringer Ingelheim Investigational Site

Edmonton, Alberta, Canada

Site Status

1220.48.1003 Boehringer Ingelheim Investigational Site

Vancouver, British Columbia, Canada

Site Status

1220.48.1016 Boehringer Ingelheim Investigational Site

Vancouver, British Columbia, Canada

Site Status

1220.48.1007 Boehringer Ingelheim Investigational Site

Victoria, British Columbia, Canada

Site Status

1220.48.1009 Boehringer Ingelheim Investigational Site

Winnipeg, Manitoba, Canada

Site Status

1220.48.1005 Boehringer Ingelheim Investigational Site

Toronto, Ontario, Canada

Site Status

1220.48.1006 Boehringer Ingelheim Investigational Site

Toronto, Ontario, Canada

Site Status

1220.48.3301 Boehringer Ingelheim Investigational Site

Clichy, , France

Site Status

1220.48.3311 Boehringer Ingelheim Investigational Site

Lille, , France

Site Status

1220.48.3303 Boehringer Ingelheim Investigational Site

Marseille, , France

Site Status

1220.48.3304 Boehringer Ingelheim Investigational Site

Montpellier, , France

Site Status

1220.48.3305 Boehringer Ingelheim Investigational Site

Nice, , France

Site Status

1220.48.3316 Boehringer Ingelheim Investigational Site

Pessac, , France

Site Status

1220.48.3312 Boehringer Ingelheim Investigational Site

Saint-Laurent-du-Var, , France

Site Status

1220.48.4902 Boehringer Ingelheim Investigational Site

Berlin, , Germany

Site Status

1220.48.4904 Boehringer Ingelheim Investigational Site

Berlin, , Germany

Site Status

1220.48.4913 Boehringer Ingelheim Investigational Site

Dortmund, , Germany

Site Status

1220.48.4906 Boehringer Ingelheim Investigational Site

Düsseldorf, , Germany

Site Status

1220.48.4901 Boehringer Ingelheim Investigational Site

Frankfurt am Main, , Germany

Site Status

1220.48.4908 Boehringer Ingelheim Investigational Site

Hamburg, , Germany

Site Status

1220.48.4914 Boehringer Ingelheim Investigational Site

Kiel, , Germany

Site Status

1220.48.4911 Boehringer Ingelheim Investigational Site

Mainz, , Germany

Site Status

1220.48.4905 Boehringer Ingelheim Investigational Site

München, , Germany

Site Status

1220.48.8106 Boehringer Ingelheim Investigational Site

Chiba, Chiba, , Japan

Site Status

1220.48.8117 Boehringer Ingelheim Investigational Site

Kita-gun, Kagawa, , Japan

Site Status

1220.48.8116 Boehringer Ingelheim Investigational Site

Kurashiki, Okayama, , Japan

Site Status

1220.48.8118 Boehringer Ingelheim Investigational Site

Kurume, Fukuoka, , Japan

Site Status

1220.48.8113 Boehringer Ingelheim Investigational Site

Nagoya, Aichi, , Japan

Site Status

1220.48.8114 Boehringer Ingelheim Investigational Site

Nishinomiya, Hyogo, , Japan

Site Status

1220.48.8119 Boehringer Ingelheim Investigational Site

Omura, Nagasaki, , Japan

Site Status

1220.48.8121 Boehringer Ingelheim Investigational Site

Osaka, Osaka, , Japan

Site Status

1220.48.3503 Boehringer Ingelheim Investigational Site

Aveiro, , Portugal

Site Status

1220.48.3509 Boehringer Ingelheim Investigational Site

Barreiro, , Portugal

Site Status

1220.48.3501 Boehringer Ingelheim Investigational Site

Lisbon, , Portugal

Site Status

1220.48.3502 Boehringer Ingelheim Investigational Site

Porto, , Portugal

Site Status

1220.48.4002 Boehringer Ingelheim Investigational Site

Bucharest, , Romania

Site Status

1220.48.7001 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

1220.48.7004 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

1220.48.8204 Boehringer Ingelheim Investigational Site

Pusan, , South Korea

Site Status

1220.48.8205 Boehringer Ingelheim Investigational Site

Pusan, , South Korea

Site Status

1220.48.8206 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

Site Status

1220.48.8207 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

Site Status

1220.48.8201 Boehringer Ingelheim Investigational Site

Yangsan, , South Korea

Site Status

1220.48.3406 Boehringer Ingelheim Investigational Site

A Coruña, , Spain

Site Status

1220.48.3402 Boehringer Ingelheim Investigational Site

Barcelona, , Spain

Site Status

1220.48.3404 Boehringer Ingelheim Investigational Site

Barcelona, , Spain

Site Status

1220.48.3411 Boehringer Ingelheim Investigational Site

Barcelona, , Spain

Site Status

1220.48.3412 Boehringer Ingelheim Investigational Site

Barcelona, , Spain

Site Status

1220.48.3405 Boehringer Ingelheim Investigational Site

Madrid, , Spain

Site Status

1220.48.3409 Boehringer Ingelheim Investigational Site

Madrid, , Spain

Site Status

1220.48.3410 Boehringer Ingelheim Investigational Site

Majadahonda-Madrid, , Spain

Site Status

1220.48.3403 Boehringer Ingelheim Investigational Site

Seville, , Spain

Site Status

1220.48.3401 Boehringer Ingelheim Investigational Site

Valencia, , Spain

Site Status

1220.48.4106 Boehringer Ingelheim Investigational Site

Bern, , Switzerland

Site Status

1220.48.8802 China Medical University Hospital

Taichung, , Taiwan

Site Status

1220.48.4405 Boehringer Ingelheim Investigational Site

Bristol, , United Kingdom

Site Status

1220.48.4409 Boehringer Ingelheim Investigational Site

London, , United Kingdom

Site Status

1220.48.4401 Boehringer Ingelheim Investigational Site

Manchester, , United Kingdom

Site Status

1220.48.4408 Boehringer Ingelheim Investigational Site

Nottingham, , United Kingdom

Site Status

1220.48.4407 Boehringer Ingelheim Investigational Site

Oxford, , United Kingdom

Site Status

1220.48.4403 Boehringer Ingelheim Investigational Site

Southampton, , United Kingdom

Site Status

1220.48.4404 Boehringer Ingelheim Investigational Site

Tooting, London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Austria Belgium Canada France Germany Japan Portugal Romania Russia South Korea Spain Switzerland Taiwan United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Foster GR, Ferenci P, Asselah T, Mantry P, Dufour JF, Bourliere M, Forton D, Maevskaya M, Wright D, Yoshida EM, Garcia-Samaniego J, Oliveira C, Wright M, Warner N, Sha N, Quinson AM, Stern JO. Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin. J Viral Hepat. 2016 Mar;23(3):227-31. doi: 10.1111/jvh.12485. Epub 2015 Nov 17.

Reference Type DERIVED
PMID: 26572686 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2011-000141-20

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

1220.48

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)
NCT01343888 COMPLETED PHASE3
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
NCT01399619 COMPLETED PHASE3
Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)
NCT00984620 COMPLETED PHASE2
A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study
NCT01609933 COMPLETED PHASE2
Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients
NCT01858961 WITHDRAWN PHASE3
Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial
NCT01579474 COMPLETED PHASE3
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
NCT01323244 COMPLETED PHASE3
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients
NCT00947349 COMPLETED PHASE2
A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment
NCT00980330 COMPLETED PHASE2
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
NCT01508130 COMPLETED
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
NCT01309932 COMPLETED PHASE2
Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)
NCT00774397 COMPLETED PHASE2
PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy
NCT00215865 COMPLETED PHASE3
A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C
NCT00332176 UNKNOWN PHASE2
A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C
NCT01591460 COMPLETED PHASE4
A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients
NCT00854802 COMPLETED NA
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
NCT00851890 COMPLETED PHASE2
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
NCT01525628 COMPLETED PHASE1
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
NCT01728324 COMPLETED PHASE3
CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
NCT00277238 COMPLETED PHASE2
Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C
NCT01859962 COMPLETED PHASE2
Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease
NCT00028093 COMPLETED PHASE4
Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)
NCT00686517 COMPLETED PHASE3
A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3
NCT01364090 COMPLETED PHASE4
Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
NCT01314261 COMPLETED PHASE2